HUTCHMED
0001317.9601.81% ( +0.320 )
HUTCHMED (00013)
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and...
- Open
- 17.550
- High
- 17.990
- Low
- 17.550
- Prev. Close
- 17.640
- Volume
- 2.04M
- Turnover
- 36.39M
- Avg Price
- 17.845
- Bid/Ask Ratio
- -70.73%
- Amplitude
- 2.49%
- 52wk High
- 30.750
- Volume Ratio
- 0.49
- Turnover Ratio
- 0.23%
HUTCHMED Analyst Rating
View MoreForecast & Rating
Jul 20, 2026Price forecast
HK$32.8382.78%
Forecast & RatingStrong buy
15analysts
- Strong buy73.33%
- Buy13.33%
- Hold13.33%
- Sell0.00%
- Strong sell0.00%
News
- CoinLive · Jul 2 at 05:33 AM
STOCKS | Hutchmed (China) Says ORPATHYS Approved in China for MET-Amplified GC/GEJ Cancer
- StockTitan · Jul 1 at 07:30 PM
HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification | HCM Stock News
- StockTitan · Jun 29 at 07:30 PM
HUTCHMED to Announce 2026 Half-Year Financial Results | HCM Stock News
- London Stock Exchange · Jun 29 at 03:30 AM
REG - Hutchmed China Ltd - Announcement on blocklisting six monthly return
- Tip Ranks · Jun 26 at 07:25 PM
HUTCHMED (China) (HCM) Gets a Buy from UBS
- benzinga_article · Jun 25 at 11:08 AM
HUTCHMED's Experimental Drug Shows Durable Responses In Advanced Bile Duct Cancer Trial
